Alx Oncology Holdings INC (ALXO) — 10-Q Filings

All 10-Q filings from Alx Oncology Holdings INC. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

ALX Oncology Narrows Q3 Loss Amidst R&D Cost Cuts — Nov 7, 2025 Risk: high
ALX Oncology Holdings Inc. reported a net loss of $22.144 million for the three months ended September 30, 2025, a 27.9% improvement from the $30.707 million ne
ALX Oncology Narrows Q2 Loss by 34% Amid R&D Spend Cuts — Aug 12, 2025 Risk: high
ALX Oncology Holdings Inc. reported a net loss of $25.949 million for the three months ended June 30, 2025, a significant improvement from the $39.399 million n
ALX Oncology Files Q1 2025 10-Q — May 8, 2025 Risk: medium
ALX Oncology Holdings Inc. reported its first quarter 2025 results on May 8, 2025. The company's financial statements for the period ending March 31, 2025, are
ALX Oncology Holdings Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
ALX Oncology Holdings Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the nine months e
ALX Oncology Holdings Q2 2024 Update — Aug 12, 2024 Risk: medium
ALX Oncology Holdings Inc. reported its financial results for the quarter ended June 30, 2024. The company's filing details its financial position and operation
ALX Oncology Holdings Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: medium
ALX ONCOLOGY HOLDINGS INC (ALXO) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. ALX Oncology Holdings Inc. filed a 10-Q report for the period endi

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX